Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Eli Lilly’s diabetes drug Mounjaro is set to join China’s state-run health insurance reimbursement list on January 1, according to the National Healthcare Security Administration. The move is expected to significantly expand access to the once-weekly injectable therapy for millions of people living with type 2 diabetes in the world’s most populous nation.
China’s inclusion of a treatment in the national reimbursement scheme typically drives widespread adoption due to lower out-of-pocket costs. However, while insurance coverage often boosts prescription volume, it can also reduce revenue per unit because pharmaceutical companies negotiate lower prices with the government. Lilly has not yet disclosed the finalized reimbursement price for Mounjaro.
Mounjaro entered the Chinese market in early 2024 following the growing success of Ozempic, a competing diabetes medication developed by Novo Nordisk. Ozempic has been available in China since 2021 and was added to the reimbursement list in 2022. Its strong market presence helped fuel sales of 5.76 billion Danish crowns (about $898.5 million) in the Greater China region in 2024, according to Novo Nordisk’s annual report.
Beyond diabetes management, China also approved Mounjaro for obesity and obstructive sleep apnea, expanding its potential reach as demand for metabolic health treatments continues to rise.
Eli Lilly’s international president, Patrik Jonsson, noted during an October earnings call that Mounjaro experienced strong “initial stocking” in major global markets outside the U.S., including China, Brazil, Mexico, and India. He added that performance improved further in the third quarter, contributing to the drug’s robust global momentum.
With Mounjaro now joining China’s reimbursement program, analysts expect increased competition in the rapidly growing diabetes and weight-management drug market, while patients stand to benefit from broader and more affordable access to innovative therapies.
